welcome
Reuters

Reuters

Health

Health

J&J to buy Intra-Cellular Therapies for $14.6 billion

Reuters
Summary
Nutrition label

76% Informative

Johnson & Johnson said on Monday it would buy drugmaker Intra-Cellular Therapies for about $14.6 billion .

The deal is the latest in a string of acquisitions by J&J as it looks to drive growth beyond 2025 .

Last year , the company acquired Numab 's skin disorder drug for $1.25 billion , and spent $850 million to buy Proteologix .

VR Score

85

Informative language

91

Neutral language

26

Article tone

formal

Language

English

Language complexity

50

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.